The Q2 performance exceeded expectations, with strong growth continuing in the key franchises, offsetting the largely-expected decline in the COVID-19 offerings. The 2023 outlook was nonetheless maintained. Although Astra’s share price has largely recovered after some initial disappointment amongst investors concerning an oncology drug’s phase III readouts in July 2023, we maintain our positive stance on Astra, backed by a healthily-growing portfolio across various therapeutic areas, an enviable ....
